文献速递白血病淋巴瘤

嵌合抗原受体T细胞(CART)在白血病中的前景

The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
PubMed 文献 · Br J Haematol · 2016-12-15

本文综述了表达嵌合抗原受体的基因工程T细胞(CART)在急性和慢性白血病中的最新临床试验数据,指出其在复发/难治性急性淋巴细胞白血病中不仅诱导缓解且维持长期疾病控制,疗效前所未有,并讨论了提升CART活性与安全性的潜在方向。

要点

  • CART在复发/难治性急性淋巴细胞白血病中可诱导缓解并维持长期疾病控制
  • 该综述汇总了急性和慢性白血病中最新CART临床试验数据
  • 文章讨论了增强CART疗效、降低毒性及拓展适应症的潜在方向

核心结论

  • CART在复发/难治性急性淋巴细胞白血病中不仅诱导缓解且维持长期疾病控制,疗效前所未有。
  • 持续开发有望改善这一新型「活体药物」的疗效、毒性及对其他恶性肿瘤的适用性。

研究设计与样本

  • 本文为综述,提供急性和慢性白血病中最新的CART临床试验数据全面概览。

主要发现

  • CART在复发/难治性急性淋巴细胞白血病中诱导缓解并维持长期疾病控制,疗效前所未有。
  • 综述汇总了急性和慢性白血病中最新CART临床试验数据。
  • 文章讨论了增强CART活性与安全性的潜在方向。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The success of genetically engineered T cells that express chimeric antigen receptors (CARTs) has been a momentous step forward in harnessing the potent cancer fighting abilities of the immune system. The efficacy seen in relapsed/refractory (r/r) acute lymphoblastic leukaemia (ALL), not only by inducing remission, but also in maintaining long-term disease control, has been unprecedented. While the foundation for this approach has been firmly set in place, continued development will improve the efficacy, toxicity and applicability to other malignancies of this new class of 'living drugs'. In this review, we provide a comprehensive overview of the most current clinical trial data in both acute and chronic leukaemias, and discuss some of the potential ways to enhance the activity and safety of CART therapy going forward.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Orlowski RJ, Porter DL, Frey NV, et al. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. Br J Haematol. 2016. PMID: 27977050. doi:10.1111/bjh.14475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。